Top Key Companies for Prescription Weight Loss Pills Market: Currax Pharmaceuticals (Contrave), VIVUS (Qsymia), Novo Nordisk A/S, Rhythm Pharmaceuticals (Imcivree), Eli Lilly and Company (TRICARE), CHEPLAPHARM (Xenical), Pfizer, Teva Pharmaceutical (Actavis), Haleon Group (alli), Sanofi (Adlyxin), AstraZeneca (BYDUREON BCise).
Global Prescription Weight Loss Pills Market Size was estimated at USD 682.65 million in 2022 and is projected to reach USD 1209.36 million by 2028, exhibiting a CAGR of 10% during the forecast period.
Global Prescription Weight Loss Pills Market Overview And Scope:
The Global Prescription Weight Loss Pills Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Prescription Weight Loss Pills utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Prescription Weight Loss Pills Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prescription Weight Loss Pills portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Prescription Weight Loss Pills market.
Global Prescription Weight Loss Pills Market Segmentation
By Type, Prescription Weight Loss Pills market has been segmented into:
Oral Tablets
Oral Capsules
Injections
By Application, Prescription Weight Loss Pills market has been segmented into:
Hospital
Pharmacy
Regional Analysis of Prescription Weight Loss Pills Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Prescription Weight Loss Pills Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Prescription Weight Loss Pills market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Prescription Weight Loss Pills market.
Top Key Companies Covered in Prescription Weight Loss Pills market are:
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Prescription Weight Loss Pills Market by Type
5.1 Prescription Weight Loss Pills Market Overview Snapshot and Growth Engine
5.2 Prescription Weight Loss Pills Market Overview
5.3 Oral Tablets
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral Tablets: Geographic Segmentation
5.4 Oral Capsules
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Oral Capsules: Geographic Segmentation
5.5 Injections
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Injections: Geographic Segmentation
Chapter 6: Prescription Weight Loss Pills Market by Application
6.1 Prescription Weight Loss Pills Market Overview Snapshot and Growth Engine
6.2 Prescription Weight Loss Pills Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Pharmacy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Pharmacy: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Prescription Weight Loss Pills Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Prescription Weight Loss Pills Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Prescription Weight Loss Pills Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CURRAX PHARMACEUTICALS (CONTRAVE)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 VIVUS (QSYMIA)
7.4 NOVO NORDISK A/S
7.5 RHYTHM PHARMACEUTICALS (IMCIVREE)
7.6 ELI LILLY AND COMPANY (TRICARE)
7.7 CHEPLAPHARM (XENICAL)
7.8 PFIZER
7.9 TEVA PHARMACEUTICAL (ACTAVIS)
7.10 HALEON GROUP (ALLI)
7.11 SANOFI (ADLYXIN)
7.12 ASTRAZENECA (BYDUREON BCISE)
Chapter 8: Global Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Oral Tablets
8.2.2 Oral Capsules
8.2.3 Injections
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Pharmacy
Chapter 9: North America Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Oral Tablets
9.4.2 Oral Capsules
9.4.3 Injections
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Pharmacy
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Oral Tablets
10.4.2 Oral Capsules
10.4.3 Injections
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Pharmacy
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Oral Tablets
11.4.2 Oral Capsules
11.4.3 Injections
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Pharmacy
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Oral Tablets
12.4.2 Oral Capsules
12.4.3 Injections
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Pharmacy
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Oral Tablets
13.4.2 Oral Capsules
13.4.3 Injections
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Pharmacy
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Prescription Weight Loss Pills Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Oral Tablets
14.4.2 Oral Capsules
14.4.3 Injections
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospital
14.5.2 Pharmacy
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Prescription Weight Loss Pills Scope:
|
Report Data
|
Prescription Weight Loss Pills Market
|
|
Prescription Weight Loss Pills Market Size in 2025
|
USD XX million
|
|
Prescription Weight Loss Pills CAGR 2025 - 2032
|
XX%
|
|
Prescription Weight Loss Pills Base Year
|
2024
|
|
Prescription Weight Loss Pills Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Currax Pharmaceuticals (Contrave), VIVUS (Qsymia), Novo Nordisk A/S, Rhythm Pharmaceuticals (Imcivree), Eli Lilly and Company (TRICARE), CHEPLAPHARM (Xenical), Pfizer, Teva Pharmaceutical (Actavis), Haleon Group (alli), Sanofi (Adlyxin), AstraZeneca (BYDUREON BCise).
|
|
Key Segments
|
By Type
Oral Tablets
Oral Capsules
Injections
By Applications
Hospital
Pharmacy
|
